Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

[1]  G. Lip,et al.  Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.

[2]  J. Halperin,et al.  Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. , 2000, The American journal of medicine.

[3]  D. Singer,et al.  Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. , 2000, Circulation.

[4]  R. Hart.  Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young , 1999, Heart.

[5]  J. Knottnerus,et al.  Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin , 1999, BMJ.

[6]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.

[7]  A Laupacis,et al.  A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. , 1999, JAMA.

[8]  R McBride,et al.  Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.

[9]  B. Gersh,et al.  Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. , 1999, Archives of internal medicine.

[10]  D. Armstrong,et al.  Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation , 1999, BMJ.

[11]  R. Kronmal,et al.  Stroke risk in an elderly population with atrial fibrillation , 1999, Journal of General Internal Medicine.

[12]  Rose Anne Kenny,et al.  Prevalence of atrial fibrillation and eligibility for anticoagulants in the community , 1998, The Lancet.

[13]  D. Einstadter,et al.  Atrial fibrillation as a risk factor for stroke: a retrospective cohort study of hospitalized Medicare beneficiaries. , 1998, American journal of public health.

[14]  Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. , 1998, Archives of internal medicine.

[15]  P. Duncan,et al.  Inaccuracy of the International Classification of Diseases (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease , 1997, Neurology.

[16]  J. Hirsh,et al.  Management of anticoagulation before and after elective surgery. , 1997, The New England journal of medicine.

[17]  The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. , 1997, Archives of internal medicine.

[18]  W. J. Hamilton,et al.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.

[19]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[20]  D K Owens,et al.  The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. , 1996, Archives of internal medicine.

[21]  D K Owens,et al.  Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, JAMA.

[22]  A. Algra,et al.  Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. , 1995, Stroke.

[23]  P. Allison.  Survival analysis using the SAS system : a practical guide , 1995 .

[24]  L. Pearce.  Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation study. , 1995, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[25]  D B Hier,et al.  Parametric modeling of stroke recurrence. , 1994, Neuroepidemiology.

[26]  R B D'Agostino,et al.  Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. , 1994, Stroke.

[27]  Eaft Study Group.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993, The Lancet.

[28]  E. Ziegel,et al.  Bootstrapping: A Nonparametric Approach to Statistical Inference , 1993 .

[29]  I. Sand.  Predictors of Thromboembolism in Atrial Fibrillation: I. Clinical Features of Patients at Risk , 1992, Annals of Internal Medicine.

[30]  S. Jencks,et al.  The health care quality improvement initiative. A new approach to quality assurance in Medicare. , 1992, Journal of the American Medical Association (JAMA).

[31]  Predictors of Thromboembolism in Atrial Fibrillation: II. Echocardiographic Features of Patients at Risk , 1992, Annals of Internal Medicine.

[32]  D. Singer,et al.  Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. , 1991, The American journal of medicine.

[33]  Elisa T. Lee,et al.  Statistical Methods for Survival Data Analysis , 1994, IEEE Transactions on Reliability.

[34]  M. Graffar.  [Modern epidemiology]. , 1971, Bruxelles medical.